QQQ   431.64 (+0.13%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.82 (-1.80%)
BABA   69.99 (-0.89%)
T   16.04 (-1.23%)
F   12.17 (-0.49%)
MU   121.26 (-0.09%)
GE   155.42 (+1.12%)
CGC   6.86 (-1.72%)
DIS   113.97 (+0.90%)
AMC   2.74 (+10.93%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.51 (-0.98%)
QQQ   431.64 (+0.13%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.82 (-1.80%)
BABA   69.99 (-0.89%)
T   16.04 (-1.23%)
F   12.17 (-0.49%)
MU   121.26 (-0.09%)
GE   155.42 (+1.12%)
CGC   6.86 (-1.72%)
DIS   113.97 (+0.90%)
AMC   2.74 (+10.93%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.51 (-0.98%)
QQQ   431.64 (+0.13%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.82 (-1.80%)
BABA   69.99 (-0.89%)
T   16.04 (-1.23%)
F   12.17 (-0.49%)
MU   121.26 (-0.09%)
GE   155.42 (+1.12%)
CGC   6.86 (-1.72%)
DIS   113.97 (+0.90%)
AMC   2.74 (+10.93%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.51 (-0.98%)
QQQ   431.64 (+0.13%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.82 (-1.80%)
BABA   69.99 (-0.89%)
T   16.04 (-1.23%)
F   12.17 (-0.49%)
MU   121.26 (-0.09%)
GE   155.42 (+1.12%)
CGC   6.86 (-1.72%)
DIS   113.97 (+0.90%)
AMC   2.74 (+10.93%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.51 (-0.98%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
$3.27
-1.5%
$4.04
$3.36
$26.30
$30.50M1.51628,703 shs34,733 shs
Ceapro Inc. stock logo
CRPOF
Ceapro
$0.18
-2.3%
$0.16
$0.11
$0.44
$13.87M1.5310,070 shs6,451 shs
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$7.85
-0.5%
$8.40
$5.01
$10.75
$10.05M0.87189,480 shs3,144 shs
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$6.50
-0.2%
$10.50
$0.29
$3.72
$276.05M3.931.22 million shs1.67 million shs
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
$0.00
$3.90
$0.46
$37.45
$1K3.3425,375 shs5,685 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
-1.51%-17.42%-31.01%-19.26%+23.86%
Ceapro Inc. stock logo
CRPOF
Ceapro
-2.32%-3.17%+9.46%+36.13%-60.64%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
-0.13%-11.35%-2.83%+54.40%+33.96%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-0.15%-0.31%-7.80%+28.46%-36.71%
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
2.00
HoldN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/AN/AN/AN/A

Current Analyst Ratings

Latest GHSI, UMRX, ZSAN, AZRX, and CRPOF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/2/2024
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/A($0.76) per shareN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
$14.49M0.96$0.06 per share2.92$0.32 per share0.55
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.82$0.14 per share56.78$6.39 per share1.23
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$22.50M12.27N/AN/A$1.04 per share6.25
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
$790K0.00N/AN/A$9.74 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/A
Ceapro Inc. stock logo
CRPOF
Ceapro
$3.38M-$0.02N/AN/A-24.95%-8.91%-7.81%N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$0.1171.37N/A0.51%2.01%1.21%5/20/2024 (Estimated)
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
-$29.92M-$14.50N/AN/A-8,375.11%-177.06%-119.14%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/A
1.33
1.33
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
11.00
7.72
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
9.01
6.98
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.18
2.90
2.90
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/A
1.61
1.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
6.27%
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
20.21%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
26.39%
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
129.33 million8.65 millionNot Optionable
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A78.29 millionN/ANot Optionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
121.28 million1.27 millionNot Optionable
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
7242.47 millionN/ANot Optionable
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
404.90 million4.78 millionNot Optionable

GHSI, UMRX, ZSAN, AZRX, and CRPOF Headlines

SourceHeadline
HOOK HOOKIPA Pharma Inc.HOOK HOOKIPA Pharma Inc.
seekingalpha.com - April 12 at 10:11 PM
Nachrichten - Weitere NachrichtenNachrichten - Weitere Nachrichten
wallstreet-online.de - January 9 at 2:39 PM
LISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy plan
pbs.org - December 6 at 7:44 AM
Der Börsen-Tag: Diese US-Aktie stürzte nachbörslich abDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich ab
n-tv.de - August 22 at 3:36 PM
East Bay Business NewsEast Bay Business News
bizjournals.com - May 18 at 9:49 PM
Mankind Pharma IPO opens on April 25, listing scheduled for May 9Mankind Pharma IPO opens on April 25, listing scheduled for May 9
moneycontrol.com - April 27 at 4:20 PM
Astellas PharmaAstellas Pharma
forbes.com - April 6 at 12:00 PM
Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation
finance.yahoo.com - February 5 at 12:11 PM
FTC asks court to hold pharma bro Martin Shkreli in contempt for failing to abide by ordersFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orders
washingtonexaminer.com - January 23 at 3:25 PM
Zosano Pharma Corporation (ZSANQ)Zosano Pharma Corporation (ZSANQ)
ca.finance.yahoo.com - November 5 at 6:33 PM
Now bank­rupt, Zosano sells off its drug de­liv­ery tech that once en­ticed No­vo Nordisk, Eli Lil­lyNow bank­rupt, Zosano sells off its drug de­liv­ery tech that once en­ticed No­vo Nordisk, Eli Lil­ly
endpts.com - October 13 at 11:22 AM
Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma GiantsBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants
msn.com - October 12 at 2:32 PM
Bankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of ClaimsBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claims
marketwatch.com - August 28 at 7:45 PM
East Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 million
bizjournals.com - August 27 at 4:10 PM
Zosano Pharma Corp (ZSANQ)Zosano Pharma Corp (ZSANQ)
investing.com - August 25 at 12:28 AM
East Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1MEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M
bizjournals.com - July 26 at 8:27 PM
A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.
bizjournals.com - July 26 at 8:27 PM
Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8
dbtnews.com - June 3 at 11:27 AM
Zosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSAN
marketwatch.com - June 2 at 3:26 PM
Why Zosano Pharma Shares Are Getting Hammered TodayWhy Zosano Pharma Shares Are Getting Hammered Today
msn.com - June 2 at 3:26 PM
Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%
seekingalpha.com - June 2 at 10:26 AM
Cash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSAN
marketwatch.com - June 2 at 10:26 AM
East Bay migraine patch developer files for bankruptcyEast Bay migraine patch developer files for bankruptcy
bizjournals.com - June 2 at 10:26 AM
Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11
finance.yahoo.com - June 2 at 10:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AzurRx BioPharma logo

AzurRx BioPharma

NASDAQ:AZRX
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.
Ceapro logo

Ceapro

OTCMKTS:CRPOF
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
Guardion Health Sciences logo

Guardion Health Sciences

NASDAQ:GHSI
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
Cogent Biosciences logo

Cogent Biosciences

NASDAQ:UMRX
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Zosano Pharma logo

Zosano Pharma

NASDAQ:ZSAN
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.